证券代码：300009 证券简称：安科生物 公告编号：2025-066 安徽安科生物工程(集团)股份有限公司 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予 股票第一个解除限售期解除限售条件部分未成就和抗肿瘤事业部 以外获授人员预留授予股票第二个解除限售期解除限售条件未成 就及回购注销部分限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要提示： 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2025 年 11 月 24 日召开了第八届董事会第二十四次会议和第八届监事会第二十二次会议，审 议通过了《关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第 一个解除限售期解除限售条件部分未成就和抗肿瘤事业部以外获授人员预留授予 股票第二个解除限售期解除限售条件未成就及回购注销部分限制性股票的议案》， 本次公司拟回购注销未满足解除限售条件的激励对象所持已获授但尚未解除限售 公司第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第一 个解除限售期解除限售条件部分未成就和抗肿瘤事业部以外获授人员预留 授予股票第二个解除 ...

Core Viewpoint - On November 21, a total of 10 listed companies will have their restricted shares unlocked, with a total market value of approximately 737 million yuan [1] Summary by Category Restricted Share Unlocking Details - The companies and their respective restricted share unlocking details are as follows: - Ice Wheel Environment (Stock Code: 000811) - 220,000 shares from equity incentive [1] - Guangji Pharmaceutical (Stock Code: 000952) - 437,400 shares from equity incentive [1] - Nanjing Pharmaceutical (Stock Code: 600713) - 493,000 shares from equity incentive [1] - Rhine Biology (Stock Code: 002166) - 3,371,500 shares from equity incentive [1] - Dawei Co., Ltd. (Stock Code: 002213) - 83,900 shares from equity incentive [1] - Anke Bio (Stock Code: 300009) - 1,784,400 shares from equity incentive [1] - Qingxin Environment (Stock Code: 002573) - 828,000 shares from equity incentive [1] - Junhe Co., Ltd. (Stock Code: 603617) - 2,490,000 shares from equity incentive [1] - Jingquan Hua (Stock Code: 002885) - 230,100 shares from equity incentive [1] - Matrix Co., Ltd. (Stock Code: 301365) - 55,032,400 shares from pre-issue restrictions [1]

Core Insights - The company reported double growth in revenue and net profit for the third quarter, primarily driven by increased sales of growth hormones and antibody drugs [1] - In the fourth quarter, the company aims to enhance operational efficiency and effectiveness, further solidifying the stable growth of its main business while accelerating the improvement of other business segments to achieve the restorative growth target set at the beginning of the year [1] Revenue and Profit Growth - The third quarter saw a significant increase in both operating income and net profit, attributed to the growth in the main business areas of growth hormones and antibody drugs [1] - The company is focused on maintaining this growth trajectory and improving overall business performance in the upcoming quarter [1] Future Outlook - The company plans to continue enhancing operational efficiency and effectiveness in the fourth quarter [1] - There is a commitment to consolidating the stable growth of the main business while also working on the improvement of other business areas [1] - The goal is to achieve the restorative growth target established at the beginning of the year [1]

证券日报网讯安科生物（300009）11月20日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司的股东总数为76058户。 ...

证券日报网讯安科生物（300009）11月20日在互动平台回答投资者提问时表示，博生吉的CD7-CAR-T 待产品获批以后，计划在"一带一路"国家进行直接申报上市的尝试。至于欧美国家，博生吉公司已经和 美国食品药品监督管理局(FDA)有过沟通，可能会使用中国的临床数据在美国直接申报注册临床Ⅱ期， 通过合作伙伴在美国开展Ⅱ期临床试验。商务拓展方面，可能会通过对外授权或者合作开发的方式展 开。 ...

每经AI快讯，有投资者在投资者互动平台提问：隆培促生长素的进展贵司有没有跟进？贵司对维昇药 业的投资是否包含相关上市承诺？ 安科生物（300009.SZ）11月20日在投资者互动平台表示，之前维昇药业与药审中心就生产细节进行沟 通，所以审评处于暂停状态，目前相关沟通已经结束，审评开关已经打开，隆培促生长素处于正常审评 中。 （文章来源：每日经济新闻） ...

在互动平台表示，博生吉的CD7-CAR-T待产品获批以后，计划在一带一路国家进行直接申报上市的尝 试。至于欧美国家，博生吉公司已经和美国食品药品监督管理局（FDA）有过沟通，可能会使用中国的 临床数据在美国直接申报注册临床II期，通过合作伙伴在美国开展II期临床。商务拓展方面，可能会通 过对外授权或者合作开发的方式展开。 ...

格隆汇11月20日丨安科生物(300009.SZ)在投资者互动平台表示，公司代理的长效促卵泡素已于11月初 正式发货，相关的市场销售情况和销售数据正在收集过程当中。 ...

Core Viewpoint - Anke Bio (300009.SZ) has officially shipped its long-acting follicle-stimulating hormone in early November, and the company is currently in the process of collecting market sales data and performance metrics [1] Group 1 - The long-acting follicle-stimulating hormone has been shipped as of early November [1] - The company is gathering information on market sales and sales data [1]

Group 1 - The technology and manufacturing sectors, along with healthcare, continue to attract significant investment, particularly in artificial intelligence, semiconductors, and biomedicine [1][2] - In the past week, there were 41 financing events in the domestic primary market, with a total scale of approximately 60.5 billion RMB [3][4] - The most active sectors included artificial intelligence, which completed 6 financing rounds totaling about 5.1 billion RMB, and biomedicine, which completed 4 rounds totaling approximately 0.8 billion RMB [4] Group 2 - Major financing activities were concentrated in Zhejiang, Jiangsu, and Guangdong provinces, with 9, 8, and 8 financing events respectively [5] - Qiming Venture Partners and Matrix Partners were among the most active investment institutions, completing 4 and 2 financing rounds respectively, primarily in technology and healthcare sectors [6] Group 3 - Jiangsu Lizhuo Information Technology received strategic investment to support its AI agriculture technology development and market expansion [7] - Zhiyou Biotech completed several million RMB in Pre-A financing to advance its core product clinical research [8] - Shenzhen Kanos Technology announced approximately 200 million USD in oversubscribed financing to accelerate commercialization and product development [9] Group 4 - Chengdu Zeling Biotech completed B++ financing, focusing on innovative drug development for cancer and autoimmune diseases [11] - Beijing Taihao Biotech secured A round financing to expedite the registration of its infectious disease diagnostic products [17] - Hangzhou Quanzhen Medical completed 100 million RMB in B round financing to enhance AI support for healthcare [19] Group 5 - Guangdong Jufeng Semiconductor completed several billion RMB in financing to support technology innovation and market expansion [30] - Wujie Power completed 300 million RMB in angel financing, focusing on robotics and intelligent operations [31] - Shanghai Yunmai Chip completed over 500 million RMB in A round financing, emphasizing cloud data center technology [35]